Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An update on the safety of SGLT2 inhibitors
André Scheen
Expert Opinion on Drug Safety (2019) Vol. 18, Iss. 4, pp. 295-311
Closed Access | Times Cited: 155

Showing 1-25 of 155 citing articles:

SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Martín Cowie, Miles Fisher
Nature Reviews Cardiology (2020) Vol. 17, Iss. 12, pp. 761-772
Closed Access | Times Cited: 576
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Anastasios Tentolouris, Panayotis K. Vlachakis, Evangelia Tzeravini, et al.
International Journal of Environmental Research and Public Health (2019) Vol. 16, Iss. 16, pp. 2965-2965
Open Access | Times Cited: 245
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
André Scheen
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 10, pp. 556-577
Closed Access | Times Cited: 230
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong Li, Junyan Zou, Wei Ran, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 152
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction
Vennela Avula, Garima Sharma, Mikhail Kosiborod, et al.
JACC Heart Failure (2023) Vol. 12, Iss. 1, pp. 67-78
Open Access | Times Cited: 43
Class effects of SGLT2 inhibitors on cardiorenal outcomes
Aaron Y. Kluger, Kristen M. Tecson, Andy Lee, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 136
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout
Chio Yokose, Natalie McCormick, Abhishek Abhishek, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 4, pp. 216-231
Closed Access | Times Cited: 13
<p>Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide</p>
Bryce C. Simes, Gordon G. MacGregor
Diabetes Metabolic Syndrome and Obesity (2019) Vol. Volume 12, pp. 2125-2136
Open Access | Times Cited: 70
Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
Francesco Giorgino, Jiten Vora, Peter Fenici, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 66
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
André Scheen, Fabrice Bonnet
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101419-101419
Open Access | Times Cited: 20
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
André Scheen
Drugs (2024)
Closed Access | Times Cited: 7
The future of new drugs for diabetes management
Clifford J. Bailey, Caroline Day
Diabetes Research and Clinical Practice (2019) Vol. 155, pp. 107785-107785
Open Access | Times Cited: 44
Class effect for SGLT-2 inhibitors: a tale of 9 drugs
Dario Giugliano, Katherine Esposito
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 43
Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study
S. T. Harris, Elisabetta Patorno, Min Zhuo, et al.
Diabetes Care (2021) Vol. 44, Iss. 10, pp. 2293-2301
Open Access | Times Cited: 39
Safety and Efficacy of Early SGLT2 Inhibitors Initiation in Diabetic Patients Following Acute Myocardial Infarction, a Retrospective Study
Gassan Moady, Igor Yakubovich, Shaul Atar
Journal of Cardiovascular Pharmacology and Therapeutics (2024) Vol. 29
Open Access | Times Cited: 5
SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art
David Aristizábal-Colorado, Martín Ocampo Posada, Wilfredo Antonio Rivera Martínez, et al.
American Journal of Cardiovascular Drugs (2024) Vol. 24, Iss. 6, pp. 707-718
Closed Access | Times Cited: 5
Effects of sodium‐glucose cotransporter‐2 inhibitors on the cardiovascular and renal complications of type 2 diabetes
Robert Ćhilton
Diabetes Obesity and Metabolism (2019) Vol. 22, Iss. 1, pp. 16-29
Closed Access | Times Cited: 42
Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
André Scheen
Diabetes & Metabolism (2020) Vol. 46, Iss. 3, pp. 186-196
Closed Access | Times Cited: 39
Targets and mechanisms of dietary anthocyanins to combat hyperglycemia and hyperuricemia: a comprehensive review
Yang Yang, Jiu‐liang Zhang, Qing Zhou
Critical Reviews in Food Science and Nutrition (2020) Vol. 62, Iss. 4, pp. 1119-1143
Closed Access | Times Cited: 37
The use of sodium‐glucose co‐transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?
Theocharis Koufakis, Омар Мустафа, Ramzi Ajjan, et al.
Journal of Clinical Pharmacy and Therapeutics (2020) Vol. 45, Iss. 5, pp. 883-891
Open Access | Times Cited: 34
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study
Avivit Cahn, Itamar Raz, Marc P. Bonaca, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 8, pp. 1357-1368
Closed Access | Times Cited: 33
Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
Thomas M. Caparrotta, Andrew M. Greenhalgh, Karen Osinski, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 4, pp. 991-1028
Open Access | Times Cited: 32
Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
Xiang Zhou, Xiaofei Ye, Xiaojing Guo, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 32
Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
Caiyun Zheng, Meimei Lin, Yan Chen, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 28
SGLT2 Inhibitors and Safety in Older Patients
Rena Pollack, Avivit Cahn
Heart Failure Clinics (2022) Vol. 18, Iss. 4, pp. 635-643
Closed Access | Times Cited: 22
Page 1 - Next Page

Scroll to top